Bladder Cancer

Rogaratinib showed similar efficacy and manageable safety compared with chemotherapy in the management of FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.

Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.

Findings from Cohort K of the EV-103 trial demonstrated a 64.5% overall response rate with enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.

At ESMO 2022, peripheral blood samples taken from patients with advanced or metastatic urothelial carcinoma treated on the phase 3 JAVELIN Bladder 100 trial showed there may be a potential to predict disease response to avelumab.

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder carcinoma in situ appear to benefit from treatment with N-803, leading to the FDA accepting its biologics license application.

Results from cohort K of the phase 1b/2 KEYNOTE-869 trial showed improved responses for patients with advanced or metastatic urothelial carcinoma when treated with enfortumab vedotin-efjv plus pembrolizumab.

Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.

A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.

Drs Gupta and Makkar discuss results from the PARADIGM cross-sectional survey, which reveals physicians’ 1L and 1LM treatment patterns in la/mUC.

Experts discuss results from the targeted literature search and qualitative interviews, which identify important factors that impact their treatment decisions for patients with locally advanced/metastatic urothelial carcinoma.

Shilpa Gupta, MD, describes the scope and methods of the PARADIGM study, which examines recent systemic anti-cancer treatment patterns in la/mUC.

Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.

Belzupacap sarotalocan received fast track designation from the FDA for and will be assessed in a phase 1 clinical trial of patients with non–muscle invasive bladder cancer.

Roger Li, MD, spoke about the safety profile of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer.

Roger Li, MD, spoke about responses from the CORE1 trial that examined patients with non–muscle invasive bladder cancer treated with CG0070 plus pembrolizumab.

Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Expert panelists focus on the treatment of metastatic urothelial cancer and discuss strategies and challenges for maintenance therapy.

A manageable safety profile and good clinical activity were observed with toripalimab in Chinese patients with urothelial carcinoma.

An exploratory analysis of the JAVELIN Bladder 100 study indicated long-term overall survival benefit for patients with advanced urothelial carcinoma who received avelumab maintenace, without regard for treatment given in the second-line setting.

Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.

Results of the COSMIC-021 trial presented at ASCO 2022 show promise of cabozantinib plus atezolizumab for urothelial carcinoma.

Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.